The transference of a part of or an entire liver from one human or animal to another.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transference of a kidney from one human or animal to another.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transference of a heart from one human or animal to another.
Transplantation of an individual's own tissue from one site to another site.
The transference of either one or both of the lungs from one human or animal to another.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transference of an organ between individuals of the same species or between individuals of different species.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The transference of a pancreas from one human or animal to another.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Elements of limited time intervals, contributing to particular results or situations.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Prospective patient listings for appointments or treatments.
Transplantation between animals of different species.
The return of a sign, symptom, or disease after a remission.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Partial or total replacement of the CORNEA from one human or animal to another.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A dead body, usually a human body.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
Pathological processes of the LIVER.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
The period following a surgical operation.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Disease having a short and relatively severe course.
Progenitor cells from which all blood cells derive.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A state of prolonged irreversible cessation of all brain activity, including lower brain stem function with the complete absence of voluntary movements, responses to stimuli, brain stem reflexes, and spontaneous respirations. Reversible conditions which mimic this clinical state (e.g., sedative overdose, hypothermia, etc.) are excluded prior to making the determination of brain death. (From Adams et al., Principles of Neurology, 6th ed, pp348-9)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Immunological rejection of leukemia cells following bone marrow transplantation.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
The chilling of a tissue or organ during decreased BLOOD perfusion or in the absence of blood supply. Cold ischemia time during ORGAN TRANSPLANTATION begins when the organ is cooled with a cold perfusion solution after ORGAN PROCUREMENT surgery, and ends after the tissue reaches physiological temperature during implantation procedures.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Providers of tissues for transplant to non-related individuals.
Tumors or cancer of the LIVER.
Excision of all or part of the liver. (Dorland, 28th ed)
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Disorders of the blood and blood forming tissues.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Small pumps, often implantable, designed for temporarily assisting the heart, usually the LEFT VENTRICLE, to pump blood. They consist of a pumping chamber and a power source, which may be partially or totally external to the body and activated by electromagnetic motors.
Solutions used to store organs and minimize tissue damage, particularly while awaiting implantation.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Adverse functional, metabolic, or structural changes in ischemic tissues resulting from the restoration of blood flow to the tissue (REPERFUSION), including swelling; HEMORRHAGE; NECROSIS; and damage from FREE RADICALS. The most common instance is MYOCARDIAL REPERFUSION INJURY.
An individual that contains cell populations derived from different zygotes.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.
Tissues, cells, or organs transplanted between genetically different individuals of the same species.
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
A tissue or organ remaining at physiological temperature during decreased BLOOD perfusion or in the absence of blood supply. During ORGAN TRANSPLANTATION it begins when the organ reaches physiological temperature before the completion of SURGICAL ANASTOMOSIS and ends with reestablishment of the BLOOD CIRCULATION through the tissue.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The process by which a tissue or aggregate of cells is kept alive outside of the organism from which it was derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Antibodies produced by a single clone of cells.
Veins which drain the liver.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Pathological processes of the KIDNEY or its component tissues.
The physiological renewal, repair, or replacement of tissue.
Testing erythrocytes to determine presence or absence of blood-group antigens, testing of serum to determine the presence or absence of antibodies to these antigens, and selecting biocompatible blood by crossmatching samples from the donor against samples from the recipient. Crossmatching is performed prior to transfusion.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The innermost membranous sac that surrounds and protects the developing embryo which is bathed in the AMNIOTIC FLUID. Amnion cells are secretory EPITHELIAL CELLS and contribute to the amniotic fluid.
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Irreversible cessation of all bodily functions, manifested by absence of spontaneous breathing and total loss of cardiovascular and cerebral functions.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
Tissue, organ, or gamete donation intended for a designated recipient.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
A general term for various neoplastic diseases of the lymphoid tissue.
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (1/9074)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Donor MHC and adhesion molecules in transplant arteriosclerosis. (2/9074)

Transplant-associated arteriosclerosis remains an obstacle to long-term graft survival. To determine the contribution to transplant arteriosclerosis of MHC and adhesion molecules from cells of the donor vasculature, we allografted carotid artery loops from six mutant mouse strains into immunocompetent CBA/CaJ recipients. The donor mice were deficient in either MHC I molecules or MHC II molecules, both MHC I and MHC II molecules, the adhesion molecule P-selectin, intercellular adhesion molecule (ICAM)-1, or both P-selectin and ICAM-1. Donor arteries in which ICAM-1, MHC II, or both MHC I and MHC II were absent showed reductions in neointima formation of 52%, 33%, and 38%, respectively, due primarily to a reduction in smooth muscle cell (SMC) accumulation. In P-selectin-deficient donor arteries, neointima formation did not differ from that in controls. In donor arteries lacking both P-selectin and ICAM-1, the size of the neointima was similar to that in those lacking ICAM-1 alone. In contrast, neointima formation increased by 52% in MHC I-deficient donor arteries. The number of CD4-positive T cells increased by 2.8-fold in MHC I-deficient arteries, and that of alpha-actin-positive SMCs by twofold. These observations indicate that ICAM-1 and MHC II molecules expressed in the donor vessel wall may promote transplant-associated arteriosclerosis. MHC I molecules expressed in the donor may have a protective effect.  (+info)

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. (3/9074)

Hematopoietic reconstitution of ablated recipients requires that intravenously (IV) transplanted stem and progenitor cells "home" to organs that support their proliferation and differentiation. To examine the possible relationship between homing properties and subsequent engraftment potential, murine bone marrow (BM) cells were labeled with fluorescent PKH26 dye and injected into lethally irradiated hosts. PKH26(+) cells homing to marrow or spleen were then isolated by fluorescence-activated cell sorting and assayed for in vitro colony-forming cells (CFCs). Progenitors accumulated rapidly in the spleen, but declined to only 6% of input numbers after 24 hours. Although egress from this organ was accompanied by a simultaneous accumulation of CFCs in the BM (plateauing at 6% to 8% of input after 3 hours), spleen cells remained enriched in donor CFCs compared with marrow during this time. To determine whether this differential homing of clonogenic cells to the marrow and spleen influenced their contribution to short-term or long-term hematopoiesis in vivo, PKH26(+) cells were sorted from each organ 3 hours after transplantation and injected into lethally irradiated Ly-5 congenic mice. Cells that had homed initially to the spleen regenerated circulating leukocytes (20% of normal counts) approximately 2 weeks faster than cells that had homed to the marrow, or PKH26-labeled cells that had not been selected by a prior homing step. Both primary (17 weeks) and secondary (10 weeks) recipients of "spleen-homed" cells also contained approximately 50% higher numbers of CFCs per femur than recipients of "BM-homed" cells. To examine whether progenitor homing was altered upon ex vivo expansion, highly enriched Sca-1(+)c-kit+Lin- cells were cultured for 9 days in serum-free medium containing interleukin (IL)-6, IL-11, granulocyte colony-stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin. Expanded cells were then stained with PKH26 and assayed as above. Strikingly, CFCs generated in vitro exhibited a 10-fold reduction in homing capacity compared with fresh progenitors. These studies demonstrate that clonogenic cells with differential homing properties contribute variably to early and late hematopoiesis in vivo. The dramatic decline in the homing capacity of progenitors generated in vitro underscores critical qualitative changes that may compromise their biologic function and potential clinical utility, despite their efficient numerical expansion.  (+info)

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. (4/9074)

The immunomodulatory effect of allogeneic blood transfusions (ABT) has been known for many years. However, a complete understanding of the effects of ABT on the recipient's immune system has remained elusive. Soluble HLA class I (sHLA-I), HLA class II (sHLA-II), and Fas ligand (sFasL) molecules may play immunoregulatory roles. We determined by double-determinant immunoenzymatic assay (DDIA) sHLA-I, sHLA-II, and sFasL concentrations in different blood components. sHLA-I and sFasL levels in red blood cells (RBCs) stored for up to 30 days and in random-donor platelets are significantly (P <.001) higher than in other blood components and their amount is proportionate to the number of residual donor leukocytes and to the length of storage. Blood components with high sHLA-I and sFasL levels play immunoregulatory roles in vitro as in allogeneic mixed lymphocyte responses (MLR) and antigen-specific cytotoxic T-cell (CTL) activity, and induce apoptosis in Fas-positive cells. These data suggest that soluble molecules in blood components are functional. If these results are paralleled in vivo, they should be taken into account in transfusion practice. Blood components that can cause immunosuppression should be chosen to induce transplantation tolerance, whereas blood components that lack immunosuppressive effects should be preferred to reduce the risk of postoperative complications and cancer recurrence.  (+info)

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (5/9074)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Risk factors for severe hemorrhagic cystitis following BMT. (6/9074)

Hemorrhagic cystitis (HC) is a common toxicity of preparative regimens for bone marrow transplantation (BMT). Severe HC often requires prolonged and expensive hospitalization, and occasionally can result in death. To investigate the risk factors for severe HC, we conducted a retrospective study among 1908 patients who received BMTs at the University of Minnesota during 1974 to 1993. A previous report from our institution reported on 977 of these patients. We identified all patients with genitourinary complication within 100 days post-BMT from the BMT database. Medical charts for these patients were reviewed to determine whether the patient had HC and also the grade of HC. A total of 208 HC cases were identified during the study period. Of them, 92 patients had severe HC, an incidence of 5% (95% CI = 4-6%). We found that grade II-IV graft-versus-host disease (RR = 2.56; 95% CI = 1.43-4.56), use of busulfan (RR = 2.69; 95% CI = 1.35-5.35), and age at transplant (RR = 2.20; 95% CI = 1.27-3.81, for age of 10-30 compared to age of 0-9) were related to an increased risk of HC. In contrast, transplant year was inversely associated with the risk of HC (trend test, P < 0.01). We did not find any significant difference in HC with the use of prophylactic Mesna.  (+info)

The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. (7/9074)

At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy.  (+info)

Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. (8/9074)

Lupus anticoagulant antibodies have never been reported to disappear after either allogeneic or autologous bone marrow transplantation in humans. We report the first case of disappearance of lupus anticoagulant antibodies in a patient without systemic lupus erythematosus or clinical evidence of other autoimmune disorders, who received an allogeneic bone marrow transplant as treatment for chronic myeloid leukemia. Although marrow transplantation is not a recognized therapy for antiphospholipid syndrome, our observation should be considered another example of the capability of intensive chemo-radiotherapy followed by stem cell transplantation to ablate a pathologic marrow clone resulting in an autoimmune disorder and improve, or even cure, some severe autoimmune diseases.  (+info)

Bone marrow transplantation, 2016; doi:10.1038/bmt.2016.123. Authors: Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G, Budde L E, Pagel J M, Frayo S L, Roden J E, Hedin L, Press O W, Gopal A K et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; City of Hope National Medical Center, Duarte, CA, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; ...
Hotels near Fred Hutchinson Cancer Research Center, Seattle on TripAdvisor: Find 111,494 traveller reviews, 50,608 candid photos, and prices for 276 hotels near Fred Hutchinson Cancer Research Center in Seattle, WA.
Cytomegalovirus (CMV) infection causes significant morbidity and mortality in the setting of immunodeficiency, including the immune reconstitution phase following allogeneic stem cell transplantation (SCT). We assessed CMV-specific CD4(+) and CD8(+) T-cell responses in 87 HLA-A*0201-positive (A2+) and/or B*0702-positive (B7+) allogeneic stem cell transplant recipients using HLA-peptide tetramer staining and cytokine flow cytometry (CFC) to examine the association of CMV-specific immune reconstitution and CMV antigenemia following SCT. Strong CMV-specific T-cell responses recovered in most subjects (77 of 87, 88%) after SCT. Frequencies of CMV-specific CD8(+) T cells were significantly higher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%, P =.0002), as were frequencies of CMV-specific CD4(+) T cells (1.71% vs 0.75%, P =.002). Frequencies of CMV-specific CD8(+) T cells were also higher in subjects experiencing late antigenemia (2.4% vs 0.57%). When we
One of the worlds leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow - not circulating, peripheral blood, which is the current norm - should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells - while the immune cells are still inside the body.. In a proof-of-principle study to be published April 17 [2017] in Nature Nanotechnology, the team showed that nanoparticle-programmed immune cells, known as T cells, can rapidly clear or slow the progression of leukemia in a mouse model.. Our technology is the first that we know of to quickly program tumor-recognizing capabilities into T cells without extracting them for laboratory manipulation, said Fred Hutchs Dr. Matthias Stephan, the studys senior author. The reprogrammed cells begin to work within 24 to 48 hours and continue to produce these receptors for weeks. This suggests that our technology has the potential to allow the immune system to quickly mount a strong enough response to destroy cancerous cells before the disease becomes ...
The Avgousti lab at the Fred Hutchinson Cancer Research Center has an opening for a postdoctoral fellow. Our laboratory uses a multidisciplinary approach to investigate the mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential. Our goal is to advance basic understanding of viral manipulation of chromatin and uncover new aspects of chromatin biology.. Much like the cellular genome, viral genomes are compacted in virus particles with small basic molecules to maximize space and be poised for gene expression. Some DNA viruses use cellular histone proteins to compact their genomes whereas others use small basic molecules. Adenoviruses encode their own histone-like protein, called protein VII, that forms a beads on a string assembly with the viral genome. By examining protein VII in host chromatin, we discovered that protein VII ...
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It
Market your lab products and lab equipment to the life science professionals at the Fred Hutchinson Cancer Research Center in Seattle, WA in the upcoming BioResearch Product Faire™ Event.
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs ...
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM. 2013. Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract ...
Hill, GR, Ferrara, JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
Bone marrow transplantation, or allogeneic hematopoietic stem cell transplant (HCT), is the only curative therapy for many patients with leukemia. Certain immune cells, called T cells, contained in the donor HCT graft can cause a graft versus leukemia (GVL) effect which eliminates leukemic cells. Unfortunately, there are also donor T cells in the HCT graft that can cause a condition called graft versus host disease (GVHD). GVHD is a life-threatening immune response that remains the major barrier to the success of transplantation. Dr. ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
平成23年4月 岡山大学病院講師(輸血部). 【一言】丁寧で安定感のある診療を心がけています。. 【研究テーマ】移植後肺合併症、ドナーリンパ球輸注によるGVL効果. 【主な業績】. ● Nishie M , Fujii N, Mimura Y , Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M. Vigorous inflammatory responses in non-infectious pulmonary complication induced by donor lymphocyte infusion. Transfusion. 2015 (in press). ● Asano T, Fujii N, Niiya D, Nishimori H, Fujii K, Matsuoka K, Ichimura K, Hamada T, Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M. Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. Springerplus. 2014 Jan 2;3:3. ● Fujii N, Nakase K, Asakura S, Matsuo K, Nawa Y, Sunami K, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, Hara M, Tanimoto M ...
HOPA supports pharmacy practitioners and seeks to promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer
Mice given short courses of anti-CD4 and anti-CD8 monoclonal antibodies became tolerant of allogeneic skin grafted at the same time. Tolerance could be obtained without T cell depletion across multiple minor antigen mismatches, both in naive and primed animals, demonstrating that peripheral T cells could be tolerized, even if they had been previously activated. Where donor and recipient were incompatible across the whole major histocompatibility complex, specific tolerance could be achieved by using a combination of depleting followed by non-depleting antibodies, where each alone was unsuccessful. Although mice clearly tolerated their original skin grafts, we observed in some strain combinations that a second fresh, but genotypically identical graft, was slowly rejected. Such mice also possessed T cells which could proliferate to donor-type stimulator cells in vitro. Whatever the mechanisms, we have demonstrated that operational transplantation tolerance can be achieved with simple, non-toxic antibody
Graft-versus-host disease remains a major cause of transplant-related mortality. Interleukin-2 plus sirolimus synergistically reduces acute graft-versus-host disease in rodents and promotes regulatory T-cells. This phase II trial tested the hypothesis that interleukin-2 would facilitate STAT5 phosphorylation in donor T-cells, expand regulatory T-cells, and ameliorate graft-versus-host disease. Between 4/16/2014-12/19/2015, 20 patients received interleukin-2 (200,000IU/m2 thrice weekly, days 0 to +90) with sirolimus (5-14ng/ml) and tacrolimus (3-7ng/ml) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation. The study was designed to capture an increase in regulatory T-cells from 16.0% to ,23.2% at day +30. Interleukin-2/sirolimus/tacrolimus significantly increased regulatory T-cells at day +30 compared to our published data with sirolimus/tacrolimus (23.8% versus 16.0%, P=0.0016; 0.052 k/ul versus 0.037 k/ul, P=0.0163), achieving the primary study endpoint. However, ...
H.Joachim Deeg from Fred Hutchinson Cancer Research CenterClinical ResearchFull Member is a speaker at Eurocancersummit-2015 conference | Conferenceseries Ltd
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma. T2 - A CIBMTR analysis. AU - Epperla, Narendranath. AU - Ahn, Kwang W.. AU - Litovich, Carlos. AU - Ahmed, Sairah. AU - Battiwalla, Minoo. AU - Cohen, Jonathon B.. AU - Dahi, Parastoo. AU - Farhadfar, Nosha. AU - Farooq, Umar. AU - Freytes, Cesar O.. AU - Ghosh, Nilanjan. AU - Haverkos, Bradley. AU - Herrera, Alex. AU - Hertzberg, Mark. AU - Hildebrandt, Gerhard. AU - Inwards, David. AU - Kharfan-Dabaja, Mohamed A.. AU - Khimani, Farhad. AU - Lazarus, Hillard. AU - Lazaryan, Aleksandr. AU - Lekakis, Lazaros. AU - Murthy, Hemant. AU - Nathan, Sunita. AU - Nishihori, Taiga. AU - Pawarode, Attaphol. AU - Prestidge, Tim. AU - Ramakrishnan, Praveen. AU - Rezvani, Andrew R.. AU - Romee, Rizwan. AU - Shah, Nirav N.. AU - Sureda, Ana. AU - Fenske, Timothy S.. AU - Hamadani, Mehdi. PY - 2019/1/10. Y1 - ...
SEATTLE - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.. Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize ...
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia. T2 - Results of a prospective observational study. AU - Schetelig, Johannes. AU - Hoek, Jennifer. AU - Stilgenbauer, Stephan. AU - Middeke, Jan Moritz. AU - Andersen, Niels Smedegaard. AU - Fox, Christopher P.. AU - Lenhoff, Stig. AU - Volin, Liisa. AU - Shimoni, Avichai. AU - Schroyens, Wilfried. AU - van Gelder, Michel. AU - Bunjes, Donald. AU - van Biezen, Anja. AU - Baldauf, Henning. AU - de Wreede, Liesbeth C.. AU - Tournilhac, Olivier. AU - Kroeger, Nicolaus. AU - Yakoub-Agha, Ibrahim. AU - Dreger, Peter. PY - 2020/8/16. Y1 - 2020/8/16. KW - FOLLOW-UP. KW - RETROSPECTIVE ANALYSIS. KW - EUROPEAN-SOCIETY. KW - CLL. KW - BLOOD. U2 - 10.1038/s41409-020-01013-y. DO - 10.1038/s41409-020-01013-y. M3 - Letter. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. ER - ...
Fred Hutchs Business Development and Industry Relations manages and commercializes our intellectual property assets. Partners are vital to the commercialization process; our goal is to work as efficiently and collaboratively as possible to achieve shared goals.
Bart L. Scott, MD, MS, is Assistant Professor at the University of Washington Medical Center and Assistant Member at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received his medical degree from the University of South Alabama and his masters of Science in Epidemiology from the University of Washington, Seattle. He completed his residency in Internal Medicine at Johns Hopkins Hospital in Baltimore, MD, where he also served as Assistant Chief of Services. His medical oncology fellowship was completed at Fred Hutchinson Cancer Research Center. Dr.
Blood, 1996; 88 (9) doi:. Authors: Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E, Furlong T, Hansen J A, Gooley T, Maher R M, Martin P, McSweeney P A, Sullivan K M, Anasetti C, Fay J W et al.(9) Affiliation: Fred Hutchinson Cancer Research Center, United States Sample size: 25 Abstract: The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. ...
Non-competitive 5K and one mile run/walk in support of research and awareness for multiple myeloma the second most common type of blood cancer.
Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.. Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is medical director of Immunotherapy Coordinating Center within the Immunotherapy Integration Hub and is medical director of the Cancer and Blood Disorders Advanced Therapeutics clinical research program.. Dr. Parks primary research focus has been investigating novel therapies for the treatment of refractory and recurrent cancers with a specific focus on high-risk neuroblastoma, a rare but aggressive form of ...
TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
PubMedID: 23505556 | Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation. | PloS one | 1/1/2013
TY - JOUR. T1 - Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. T2 - a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. AU - Ohashi, Kazuteru. AU - Nagamura-Inoue, Tokiko. AU - Nagamura, Fumitaka. AU - Tojo, Arinobu. AU - Miyamura, Kouichi. AU - Mori, Takehiko. AU - Kurokawa, Mineo. AU - Taniguchi, Shuichi. AU - Ishikawa, Jun. AU - Morishima, Yasuo. AU - Atsuta, Yoshiko. AU - Sakamaki, Hisashi. PY - 2014/9/1. Y1 - 2014/9/1. N2 - We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic ...
TY - JOUR. T1 - Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. AU - Balassa, Katalin. AU - Krahling, Tunde. AU - Remenyi, Peter. AU - Batai, Arpad. AU - Bors, Andras. AU - Kiss, Katalin Piroska. AU - Torbagyi, Eva. AU - Gopcsa, Laszlo. AU - Lengyel, Lilla. AU - Barta, Aniko. AU - Varga, Gergely. AU - Tordai, A.. AU - Masszi, T.. AU - Andrikovics, H.. PY - 2016/7/7. Y1 - 2016/7/7. N2 - Several genetic polymorphisms have been implicated to affect the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of cytokines in acute graft-versus-host disease (aGvHD) is well established and many of the involved cytokines signal through the Janus kinase (JAK) pathways. In this study, we assessed the association of recipient and donor JAK2 46/1 haplotypes and allo-HSCT outcome in a cohort of 124 acute myeloid leukemia patients. Both, recipient and donor 46/1 haplotypes ...
TY - JOUR. T1 - Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. AU - Anderson, Larry D.. AU - Savary, Cherylyn A.. AU - Mullen, Craig A.. PY - 2000/4/1. Y1 - 2000/4/1. N2 - Allogeneic bone marrow transplantation (BMT) induces 2 closely associated immune responses: graft-versus-tumor (GVT) activity and graft- versus-host disease (GVHD). We have previously shown that pretransplant immunization of allogeneic BMT donors with a recipient-derived tumor cell vaccine increases both GVT activity and lethal GVHD because of the priming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor vaccine cells. The work reported here tested the hypothesis that tumor cell vaccination after BMT would produce an increase in GVT activity without exacerbating GVHD. C3H.SW donor bone marrow and splenocytes were transplanted into major histocompatibility ...
BACKGROUND & OBJECTIVE: Patients with refractory or relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation had a poor prognosis with high death rate due to relapse or transplant-related mortality (TRM). The purpose of this paper was to clarify the role of inducing acute graft-versus-host disease (aGVHD) during transplantation in preventing relapse.. METHODS: Thirty adult patients with refractory or relapsed leukemia were acute lymphoblastic leukemia (n=16), acute myelogenous leukemia (n=10), and acute mixed leukemia (n=4). They were in first complete remission (n=4), second complete remission (n=9), partly remission (n=12), and non-response (n=5) at the time of transplantation. Patients underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-identical siblings (n=21), mismatched siblings donors (n=3), and allogeneic bone marrow transplantation (n=5) or allo-PBSCT (n=1) from unrelated HLA matched donors. All patients received myeloablative ...
TY - JOUR. T1 - Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. AU - Fujii, Nobuharu. AU - Ikeda, Kazuma. AU - Koyama, Motoko. AU - Aoyama, Kazutoshi. AU - Masunari, Taro. AU - Kondo, Eisei. AU - Matsuzaki, Takashi. AU - Mizobuchi, Satoshi. AU - Hiraki, Akio. AU - Teshima, Takanori. AU - Shinagawa, Katsuji. AU - Ishimaru, Fumihiko. AU - Tanimoto, Mitsune. PY - 2006/6/1. Y1 - 2006/6/1. N2 - The calcineurin inhibitors (CIs) cyclosporine A and tacrolimus are essential for graft-versus-host disease prophylaxis but are associated with adverse effects, including neurotoxicity. We report a case of irreversible CI-induced neuropathic pain following allogeneic hematopoietic stem cell transplantation. The patient developed dysesthesia, electric shock-like pain, and severe itching followed by intractable analgesic-resistant pain in the lower extremities. There were no abnormal radiographic findings, and there was no improvement with a ...
Purpose of reviewCytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is no
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
The University of Washington and Fred Hutchinson Cancer Research Center have been awarded a four-year $4.8 million contract by the National Human Genome Research Institute (NHGRI) of the National Inst...
Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups, and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at three years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively ...
TY - JOUR. T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. AU - Lupo-Stanghellini, Maria Teresa. AU - Provasi, Elena. AU - Bondanza, Attilio. AU - Ciceri, Fabio. AU - Bordignon, Claudio. AU - Bonini, Chiara. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most ...
TY - JOUR. T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. AU - Saburi, Masuho. AU - Kohashi, Sumiko. AU - Kato, Jun. AU - Koda, Yuya. AU - Sakurai, Masatoshi. AU - Toyama, Takaaki. AU - Kikuchi, Taku. AU - Karigane, Daiki. AU - Yuda, Sayako. AU - Yamane, Yusuke. AU - Hashida, Risa. AU - Abe, Ryohei. AU - Nakazato, Tomonori. AU - Hirahashi, Junichi. AU - Ogata, Masao. AU - Okamoto, Shinichiro. AU - Mori, Takehiko. PY - 2017/5/17. Y1 - 2017/5/17. N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT ...
EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022 For correspondence: Elena Vladislavovna Morozova, MD, PhD, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022; e-mail: [email protected] For citation: Morozova EV, Vlasova YuYu, Barabanshchikova MV, et al. Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors. Clinical oncohematology. 2020;13(2):193-8 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-193-198 ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a radical method of chronic myeloid leukemia (CML) treatment. In the 1990s CML became the most frequent
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk cytogenetics ...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
TY - JOUR. T1 - Vitamin D level after allogeneic hematopoietic stem cell transplant. AU - Sproat, Lisa. AU - Bolwell, Brian. AU - Rybicki, Lisa. AU - Dean, Robert. AU - Sobecks, Ronald. AU - Pohlman, Brad. AU - Andresen, Steven. AU - Sweetenham, John. AU - Copelan, Edward. AU - Kalaycio, Matt. PY - 2011/7. Y1 - 2011/7. N2 - Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/osteopenia. We therefore studied the incidence of ...
The purpose of this study is to evaluate the outcome of imatinib combined with reduced-intensity allogeneic hematopoietic stem cell transplantation versus
PubMed journal article: Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Download Prime PubMed App to iPhone, iPad, or Android
Introduction. Cyclosporin (CSA) is commonly used as graft vs host disease (GvHD) prophylaxis in allogeneic haematopoietic stem cell transplant (alloHSCT) recipients. The usual IV dose is 3mg/kg and the recommended oral dose at switching is 3mg/kg BD in the pre-posaconazole era (Inoue et al. 2014). Posaconazole is now commonly used as antifungal prophylaxis in this context; it increases CSA levels through inhibition of the cytochrome involved in CSA metabolism (Sánchez-Ortega et al. 2012). We evaluated CSA-related toxicity after switch from IV to oral CSA in alloHSCT recipients receiving posaconazole with the aim of defining the optimal weight based oral dose.. Methods. A retrospective audit was performed of adult alloHSCT patients between October 2015 and October 2017 who received IV and then oral CSA together with posaconazole prophylaxis. Posaconazole was commenced during conditioning and continued at 300mg IV or oral daily according to gastrointestinal tolerance; patients with levels below ...
These experiments explored mechanisms of control of acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation using a murine model of MHC-matched, minor histocompatibility antigen mismatched transplantation. The central hypothesis examined was that addition of active vaccination against leukemia cells would substantially increase the effectiveness of allogeneic donor lymphocyte infusion against ALL present in the host after transplant. While vaccination did increase the magnitude of type I T cell responses against leukemia cells associated with donor lymphocyte infusion, it did not lead to substantial improvement in long term survival. Analysis of immunological mechanisms of leukemia progression demonstrated that the failure of vaccination was not due to antigen loss in leukemia cells. However, analysis of survival provided surprising findings that, in addition to very modest type I T cell responses, a B cell response that produced antibodies that bind leukemia ...
Yi-Bin Chen, Massachusetts General Hospital, Boston, US, and colleagues explored the potential benefits of coadministration of vedolizumab with standard GvHD prophylaxis in a phase Ib study
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant diseases, as well as a small proportion of non-malignant disorders. The treatment before the HSCT (called conditioning) can be either myeloablative (MAC) or given with reduced intensity (RIC). MAC is associated with high toxicity due to high doses of chemotherapy with or without total body irradiation (TBI), and is used in both autologous and allogeneic HSCT. In autologous HSCT the patient is the donor, and in allogeneic HSCT the donor is a sibling or an unrelated donor. RIC regimens are associated with reduced toxicity and are only for patients undergoing allogeneic HSCT. Both autologous and allogeneic HSCT have a strong effect on the patients health-related quality of life (HRQL). The two studies in this thesis were initiated when RIC was introduced at a hematological department in south-east Sweden in 2001. The overall purpose was to evaluate HRQL in patients undergoing HSCT. The studies ...
TY - JOUR. T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. AU - Muramatsu, Hideki. AU - Sakaguchi, Hirotoshi. AU - Taga, Takashi. AU - Tabuchi, Ken. AU - Adachi, Souichi. AU - Inoue, Masami. AU - Kitoh, Toshiyuki. AU - Suminoe, Aiko. AU - Yabe, Hiromasa. AU - Azuma, Eichi. AU - Shioda, Yoko. AU - Ogawa, Atsushi. AU - Kinoshita, Akitoshi. AU - Kigasawa, Hisato. AU - Osugi, Yuko. AU - Koike, Kazutoshi. AU - Kawa, Keisei. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Kudo, Kazuko. PY - 2014/5. Y1 - 2014/5. N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
指紋 深入研究「Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia」主題。共同形成了獨特的指紋。 ...
Rabbit polyclonal to Dynamin-1.Dynamins represent one of the subfamilies of GTP-binding proteins.These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain.Dynamins are associated with microtubules.. black individuals from the prior research had been lost to check out up. Three brand-new alloHSCT recipients had been enrolled. We contacted five entitled alloHSCT recipients to sign up the three brand-new alloHSCT SDZ 220-581 Ammonium salt individuals. HSCT and matched-control individuals had been enrolled more than a 15-month period. The matched-control and alloHSCT characteristics are summarized in Desk 1. All individuals had been Caucasian. AlloHSCT was connected with postponed maturation. Elevation Z-scores had been markedly low in alloHSCT individuals while BMI Z-scores didnt differ considerably. AlloHSCT sitting elevation relative to elevation was considerably lower in comparison to handles (p ...
Hematopoietic Cell Transplantation, 2nd ed. Blackwell Science, London, 1999, pp. 823-834. 3. Forman SJ, Krance RA, ODonnell MR, et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors. Transplantation 1987;43:650-653. 4. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. 59. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998;12 (suppl. 1):S25-S29. Chapter 2 / Allogeneic BMT for AML 27 60. Fefer A. Graft-versus-tumor responses. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Blackwell ...
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant
Background: Renal dysfunction after allogeneic hematopoietic stem cell transplantation (HSCT) has been increasingly reported. However, there are few reports on the changes of the estimated glomerular filtration rate (eGFR) in long-term survivors after allogeneic HSCT. Patients and methods: The medical records at Seoul St. Marys Hospital in Korea were reviewed to identify all adult (, 18 years of age) patients who had undergone high-dose chemotherapy and allogeneic HSCT between January 2001 and December 2005. Among these patients, those with , 5 years of follow-up and relapse within 5 years after HSCT were excluded. 85 patients were enrolled. Results: The mean follow-up was 76.0 +/- 13.5 months. The eGFR recorded 3 months after HSCT was significantly decreased compared with the eGFR recorded before HSCT. Subsequently, early decreased eGFR was maintained during the 60 months after HSCT. Multivariate analysis showed that acute kidney injury (AKI) during HSCT, hypertension (HTN) and eGFR before ...
Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.
Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host DiseaseConference abstracts...
Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related disorders - Part I ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - UR - U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
Full text of Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation 1st ed. (2013) Gerard Socie and B.R. Blazar is part of the ScienceDirect eBook Collection. For USC users only. Requires USC network connection.. ...
This retrospective report compared the results of graft source on outcome after allogeneic stem cell transplantation (allo-SCT) in patients with hematologic malignancies receiving a reduced intensity conditioning (RIC) regimen. A total of 152 patients received either a RIC allo-SCT using a 9/10 mismatched unrelated donor (MisMUD, n=42) or a double unrelated umbilical cord blood (dUCB, n=110) graft. With a median follow-up of 30.3 months, the cumulative incidence of non-relapse mortality was 26% in the dUCB group versus 24% in the MisMUD group (P=0.95). Grade 3-4 acute graft-versus-host disease (GVHD) incidence was 19.7% in the dUCB group versus 21.4% in the MisMUD group (P=0.83). The cumulative incidence of extensive chronic GVHD at 2 years was 6.4% in the dUCB group versus 21.4% in the MisMUD group (P=0.02). The Kaplan-Meier estimate of overall survival at 2 years was comparable between both groups (52.3% (95% confidence interval (CI), 42.1-61.5%) in the dUCB group versus 47.9% (95% CI, 31.6-62.4%) in
ISBN 978-1-4377-1753-2. Tenenhouse HS (February 1999). "X-linked hypophosphataemia: a homologous disorder in humans and mice". ... Nephrology, Dialysis, Transplantation. 14 (2): 333-41. doi:10.1093/ndt/14.2.333. PMID 10069185. Sodium-Phosphate+Cotransporter+ ...
Sen, PK; Parulkar, GB; Panday, SR; Kinare, SG (1965). "Homologous canine heart transplantation: a preliminary report of 100 ... Cooper, D. K. C. (1 July 1969). "Transplantation of the heart and both lungs: I. Historical review". Thorax. 24 (4): 383-390. ... Kalra, Aakshi; Seth, Sandeep; Hote, Milind Padmaker; Airan, Balram (1 May 2016). "The story of heart transplantation: From cape ...
Heart transplantation in Chagas' disease. 10 years after the initial experience. Circulation. 1996 Oct 15;94(8):1815-7. PMID ... Results of replacement of cardiac valves by homologous dura mater valves. Chest. 1975 Jun;67(6):706-10. PMID 123848 Barbero ... Experience on three cases of human heart transplantation. Laval Med. 1970 Feb;41(2):149-54. PMID 4929483 Losardo RJ et al. ... He is internationally known for performing the first heart transplantation in Latin America in 1968, and for creating the ...
Milachowski, KA; Weismeier, K; Wirth, CJ (1989). "Homologous meniscus transplantation. Experimental and clinical results". ... Early reports of meniscus transplantation done in arthritic knees suggested a higher incidence of transplantation failure if ... Meniscal transplantation is a novel surgical technique designed to improve the biology and biomechanics of a meniscus deficient ... Meniscal transplantation is technically difficult, as it must be sized accurately for each person, positioned properly and ...
... are allowed to be an object of manufacture and homologous transplantation in USA and European ... 1158n "On amending the list of transplantation objects". According to the Order, cells obtained from the biomaterial by its ... Minimally manipulated cells are allowed to be an object of transplantation, when they do not contain any other substances ... 1158 "On amending the list of transplantation objects"; 2020. Available from: ...
2. Vascularization of autologous and homologous implants of cortical bone in rats". The British Journal of Experimental ... Transplantation. 11 (2): 128-134. doi:10.1097/00007890-197102000-00004. PMID 5578737.(subscription required) Heslop, Barbara F ... Manifestations of immunological tolerance to implants of homologous cortical bone in rats". The British Journal of Experimental ... A comparison of autologous and homologous bone implants with reference to osteocyte survival, osteogenesis and host reaction". ...
All structures are as yet considered as homologous. This view is substantiated by the common expression of several genes, ... including goosecoid, Cnot, noggin, nodal, and the sharing of strong axis-inducing properties upon transplantation. Cell fate ... the amniote primitive streak and the amphibian blastopore are homologous structures, that have evolved from one and the same ...
Humanized models also aid in testing new therapies Studying allograft rejection after pancreatic islet transplantation therapy ... homologous to IL2RG in humans). IL2Rγ is a common component of the cell surface receptors that bind and transduce signals from ... or for long-term transplantation studies. The Il2rgtm1Wjl targeted mutationb is a complete null mutation in the gene encoding ...
... awarded a Hunterian Professorship of the Royal College of Surgeons of England for his lecture The transplantation of homologous ... The Transplantation of Tissues and Organs. Charles C. Thomas. Springfield, Illinois 1960. The One and the Many: Edwin Stevens ... "History of Kidney Transplantation in Edinburgh". Archived from the original on 6 February 2009. Retrieved 30 November 2008. " ... As a major part of his research, Woodruff served as the honorary director of a Research Group on Transplantation established by ...
From 1960 to 1965 Dausset worked primarily on improving organ transplantation techniques and the mechanisms involved in ... and the discovery that Hu-1 is homologous to the mouse H-2 complex, which also functions in histocompatibility. Toward the end ... transplantation immunogenetics research unit. Dausset founded France Transplant and France Greffe de Moelle, which brings ... a conclusion which would in time have profound effects on the transplantation process. In the years to come, Dausset continued ...
... as well as other studies on homologous and/or autologous transplantation for DLBCL-RT, selected individuals for transplantation ... Hematopoietic stem cell transplantation in 7 of these individuals did not improve their median overall survival times. Based on ... Patients with DLBCL-RT have been treated with autologous or allogenic hematopoietic stem cell transplantation. In these ... "Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review ...
Non-homologous end joining (NHEJ) is a pathway that repairs double-strand breaks in DNA. NHEJ is referred to as "non-homologous ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it is reserved for ... This phenomenon is used in bone marrow transplantation, when a small number of Hematopoietic stem cells reconstitute the ...
... meaning nothing homologous with LDV in mice has been found in another species. LDV was discovered in 1960 by Dr. Vernon Riley ... activity within three days of the transplantation. This occurred even before the tumors were obvious clinically. In further ...
Medawar, P. B. (2017-01-04). "Immunity to Homologous Grafted Skin. III. The Fate of Skin Homographs Transplanted to the Brain, ... In another study on type II diabetic and obese mice, the transplantation of microencapsulated Sertoli cells in the subcutaneous ... Garrett JC, Steensen RN, Stevensen RN (1991). "Meniscal transplantation in the human knee: a preliminary report". Arthroscopy: ... Taylor, Andrew W. (2016-01-01). "Ocular Immune Privilege and Transplantation". Frontiers in Immunology. 7: 37. doi:10.3389/ ...
Canadian Transplantation Society [4], XVII World Congress of The Transplantation Society Inc. [5], is a Fellow of the Royal ... Guttmann, R.D., Aust, J.B.: Acquired tolerance to homografts produced by homologous spleen cell injection in adult mice. Nature ... now called American Society of Transplantation. [16](1982). Co-founder and president of the Canadian Transplantation Society [ ... Transplantation Reviews 6:189-193, 1992. cited in: Human Rights Watch Report on Judicial Execution in China.[19] Guttmann, R.D ...
... base pair birth defect bone marrow transplantation cancer candidate gene carcinoma carrier cDNA library cell centimorgan ... line haploid haploinsufficiency hematopoietic stem cell heterozygous highly conserved sequence holoprosencephaly homologous ...
... which has a similar structure to red pulp and is presumed homologous with the spleen of higher vertebrates. In mice the spleen ... vein and its tributaries Spleen Laparoscopic view of human spleen Asplenia with cardiovascular anomalies Spleen transplantation ...
There are homologous tissues to the endosternite cartilage in other arthropods. The embryos of Limulus polyphemus express ColA ... This property allows for the transplantation of cartilage from one individual to another without fear of tissue rejection. ...
... protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to ... Hemophilia A has been corrected by liver transplantation. Transplanting hepatocytes was ineffective, but liver endothelial ...
Experiments show that transplantation of other types of veto cells along with megadose haploidentical HSCT allows to reduce the ... Immunological methods utilize antibodies, either alone, in conjunction with homologous, heterologous, or rabbit complement ... This procedure is called 'megadose transplantation' and it prevents rejection because the stem cells have an ability (i.e. veto ... TCD is heavily used in haploidentical stem cell transplantation (HSCT), a process in which cancer patients receive an infusion ...
... "homologous") molecules of DNA, especially that which occurs between homologous chromosomes. The term may refer to the ... by allogeneic transplantation of cells, tissues, or organs from a genetically non-identical donor); in plants, it can result ... homeobox homologous chromosomes A set of two matching chromosomes, one maternal and one paternal, which pair up with each other ... homologous recombination A type of genetic recombination in which nucleotide sequences are exchanged between two similar or ...
... "homologous") molecules of DNA, especially that which occurs between homologous chromosomes. The term may refer to the ... by allogeneic transplantation of cells, tissues, or organs from a genetically non-identical donor); in plants, it can result ... they do not occupy homologous loci on homologous chromosomes). pseudogene A non-functional sequence of DNA that resembles a ... homeobox homologous chromosomes A set of two matching chromosomes, one maternal and one paternal, which pair up with each other ...
"NHEJ1 non-homologous end joining factor 1 [Homo sapiens (human)] - Gene - NCBI". Retrieved 2017-07-13. " ... one finds that treatment with allogeneic hematopoietic stem cell transplantation, which are stem cells that bring about other ... is 219,075,324 to 219,160,865 The pathophysiology of Cernunnos deficiency begins with normal function of Non-homologous end- ...
"Abo Compatibility and Acute Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation". Transplantation. 45 (6 ... "controlled at a single gene locus or by two or more very closely linked homologous genes with little or no observable ... It is also used before hematopoietic stem cell transplantation, as it may be responsible for some cases of acute graft-versus- ...
However, homologous recombinational repair of DNA double-strand breaks mediated by BRCA1 and ATM weakens with age in oocytes of ... Alternatively to the autologous transplantation, the development of culture systems that support oocyte development from the ... such as homologous recombination. Some algae and the oomycetes produce eggs in oogonia. In the brown alga Fucus, all four egg ... the germline during the decades long period in humans between early oocytogenesis and the stage of meiosis in which homologous ...
September 2003). "Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis ... transplantation immunity and tumor immunity. ICOSLG is also a major costimulator in endothelial cell-mediated T cell activation ... a T cell-specific costimulatory molecule homologous to CD28 and CTLA-4. In humans, ICOSLG binds to ICOS but also to CD28 and ...
For instance, human foreskin fibroblasts, one type of somatic cell, use non-homologous end joining (NHEJ), an error prone DNA ... On January 23, 2009, Phase I clinical trials for transplantation of oligodendrocytes (a cell type of the brain and spinal cord ... The major concern with the possible transplantation of ESCs into patients as therapies is their ability to form tumors ... Thus, mouse ES cells predominantly use high fidelity homologous recombinational repair (HRR) to repair DSBs. This type of ...
1989). "20 KDa homologous restriction factor of complement resembles T cell activating protein". Biochem. Biophys. Res. Commun ... Transplantation. 57 (10): 1494-501. doi:10.1097/00007890-199405000-00017. PMID 7515200. Wikimedia Commons has media related to ... 1990). "Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal ... regulates the action of the complement membrane attack complex on homologous cells". J. Exp. Med. 170 (3): 637-654. doi:10.1084 ...
The CtlP and Mre11 nuclease complex are essential for accurate processing and repair of double-strand breaks during homologous ... The basis for clonal aging was clarified by transplantation experiments of Aufderheide in 1986. When macronuclei of clonally ...
Transplantation of a single neoblast to a fatally injured animal has been shown to rescue the animal An analysis of the genome ... Two protein components have been found within the chromatoid bodies DjCBC-1 and SpolTud-1, which are homologous to proteins ... Transplantation of just one clonogenic neoblast, a worm with no neoblast, restored all the organism's cells. One single ... neoblast can regenerate an entire irradiated animal that has been rendered incapable of regeneration following transplantation ...
Nucleus transplantation experiments in mouse zygotes in the early 1980s confirmed that normal development requires the ... arguing that natural selection is operating on the role of epigenetic marks as machinery for homologous chromosome recognition ...
Somatic cell nuclear transplantation has become a focus of study in stem cell research. The aim of carrying out this procedure ... though questions remain on how homologous the two cell types truly are. Somatic cell nuclear transfer is a technique for ...
Clarkson K, Rosenfeld B, Fair J, Klein A, Bell W (Dec 1991). "Factor XI deficiency acquired by liver transplantation". Annals ... a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry. 25 (9 ... a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry. 25 (9 ...
Experiments using intrahippocampal transplantation of hippocampal cells in primates with neurotoxic lesions of the hippocampus ... but they have one that is considered homologous to it. The hippocampus, as pointed out above, is in essence part of the ...
Then, homologous recombination occurs naturally within some cells, replacing the gene of interest with the designed transgene. ... adapting animal organs for transplantation into humans, and the production of pharmaceutical products such as insulin, growth ...
"Epiretinal Transplantation of Human Bone Marrow Mesenchymal Stem Cells Rescues Retinal and Vision Function in a Rat Model of ... "Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats". Nature Medicine. 4 (7): 814- ...
1958 Jan;4(1):82-8. Effect of homologous bone marrow-spleen cell suspension on survival of swine exposed to radiation from a ... sub-dermal bone transplantation, and consumption of radio-labeled iron. In the winter of 1952-1953, he volunteered to be sent ...
In mice the MHC locus known as IA is homologous to human HLA DQ. Several autoimmune diseases that occur in humans that are ... The name 'HLA DQ' originally describes a transplantation antigen of MHC class II category of the major histocompatibility ... complex of humans; however, this status is an artifact of the early era of organ transplantation. HLA DQ functions as a cell ...
H-13, a new histocompatibility locus in the fifth linkage group". Transplantation. 5 (3): 492-503. doi:10.1097/00007890- ... 2005). "Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of ...
This difference suggests that vertebrate and cephalopod eyes are not homologous, but have evolved separately. From an ... Reports on implant research at Technology Review Successful photoreceptor transplantation, MIT Technology Review, November 2006 ... November 2006). "Retinal repair by transplantation of photoreceptor precursors" (PDF). Nature. 444 (7116): 203-207. Bibcode: ... cells integrate into the outer nuclear layer and differentiate into mature photoreceptors after subretinal transplantation into ...
... non-homologous end-joining and homologous recombinational repair (HRR) (see chart in DNA repair) and reference. Only HRR can ... 2008). 'Metabolic Management - Organ Procurement and Preservation For Transplantation. New York: Landes Bioscience Springer. ... The HRR pathway requires that a second homologous chromosome be available to allow recovery of the information lost by the ... Experimentally, mutation rates increase substantially in cells defective in DNA mismatch repair or in Homologous ...
Liu X, Han Y, Yuen D, Ma B (September 2009). "Automated protein (re)sequencing with MS/MS and a homologous database yields ... Milland J, Sandrin MS (December 2006). "ABO blood group and related antigens, natural antibodies and transplantation". Tissue ... The variable domain exon is rejoined through a process called non-homologous end joining (NHEJ) to the desired constant region ...
... homologous MeSH E02.875.800.500 - embryo transfer MeSH E02.875.800.750 - fertilization in vitro MeSH E02.875.800.750.700 - ... transplantation conditioning MeSH E02.095.520.750 - radioimmunotherapy MeSH E02.095.682.884 - tissue therapy MeSH E02.120. ... homologous MeSH E02.875.800.968 - oocyte donation MeSH E02.875.800.984 - ovulation induction MeSH E02.875.800.984.500 - ...
April 2017). "Aging impairs double-strand break repair by homologous recombination in Drosophila germ cells". Aging Cell. 16 (2 ... "Germ plasm and germ cell determination in Xenopus laevis as studied by cell transplantation analysis". Cold Spring Harbor ...
LAK cells have anticancer efficacy against homologous carcinoma cells and can grow ex vivo in the presence of IL-2. In melanoma ... Maeta N, Tamura K, Takemitsu H, Miyabe M (July 2019). "Lymphokine-activated killer cell transplantation after anti-cancer ...
Wellems, T. E.; Howard, R. J. (1 August 1986). "Homologous genes encode two distinct histidine-rich proteins in a cloned ... Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation. "Kinghorn ...
There are three main types of disease models: homologous, isomorphic and predictive. Homologous animals have the same causes, ... For example, the results have included the near-eradication of polio and the development of organ transplantation, and have ... The cell cycle in a simple yeast is very similar to the cell cycle in humans and is regulated by homologous proteins. The fruit ... Animal models can be classified as homologous, isomorphic or predictive. Animal models can also be more broadly classified into ...
Dialysis and kidney transplantation are used to treat kidney failure; one (or both sequentially) of these are almost always ... The collecting ducts from each cluster of nephrons usually drain into an archinephric duct, which is homologous with the vas ... Renal replacement therapy, in the form of dialysis or kidney transplantation, is indicated when the glomerular filtration rate ... these are never homologous with the kidneys of vertebrates, and are more accurately referred to by other names, such as ...
FA is the result of a genetic defect in a cluster of proteins responsible for DNA repair via homologous recombination. ... A more permanent cure is hematopoietic stem cell transplantation. If no potential donors exist, a savior sibling can be ... 2013). "Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the EBMT experience". Blood. 122 (26): 4279-4286 ... specifically homologous recombination, and given the current knowledge about dynamic cell division in the bone marrow, patients ...
Homologous ✖ Remove constraint Subject: Transplantation, Homologous Exhibit Tags hypothermia ✖ Remove constraint Exhibit Tags: ... Start Over You searched for: Creator Morfit, H. Mason ✖ Remove constraint Creator: Morfit, H. Mason Subject Transplantation, ...
Results of search for su:{Transplantation, Homologous} Refine your search. *. Availability. * Limit to currently available ... Human fetal tissue transplantation research : report of the Advisory Committee to the Director, National Institutes of Health, ... Report of the Human Fetal Tissue Transplantation Research Panel, December 1988 / consultants to the Advisory Committee to the ... by Human Fetal Tissue Transplantation Research Panel , Advisory Committee to the Director, National Institutes of Health. ...
Massive reflux is an indication for pre-transplantation nephroureterectomy. Reconstructive o … ... Of patients undergoing renal transplantation during a recent 18-month period 42 per cent had significant urologic abnormalities ... Renal transplantation in patients with urologic abnormalities J Urol. 1976 May;115(5):490-3. doi: 10.1016/s0022-5347(17)59252-6 ... Patients with a variety of abnormalities of the urinary tract had a transplantation success rate comparable to that of azotemic ...
... raising the question of whether transplantation can eradicate the HIV reservoir. To test this, we here present a model of allo- ... Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, ... Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether ... Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation Nat ...
... and the Transplantation Research Platforms Start-Up Grant 2020 (to Andreas Heinzel) ... Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients. Andreas Heinzel, Eva ... Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients ... Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients ...
Homologous Transplantation (Allograft) ...
A central role for active tolerance in transplantation-tolerance is also supported by recent data showing that genuine ... We discuss here recent advances obtained by combining regulatory T cell infusion with bone-marrow transplantation. In ... It has been proposed that bone marrow or hematopoietic stem-cell transplantation, and resulting (mixed) hematopoietic chimerism ... It is widely believed that bone marrow or hematopoietic stem cell transplantation, and resulting (mixed) hematopoietic ...
NK Cells, Their Receptors, Transplantation and Cancer Th. Miller, J. S., Cooley, S. A., Ho, Y., Le, C. T., Luo, X., Tolar, J., ... Enhancing the Safety of Allogeneic Transplantation. Weisdorf, D. J., Arora, M., Brunstein, C. G., McClune, B. L. & Wagner, J. E ... Enhancing the Safety of Allogeneic Transplantation. Weisdorf, D. J., Arora, M., Brunstein, C. G., McClune, B. L. & Wagner, J. E ... Project 2: (Bhatia/Bhatia) Therapy-related leukemia following autologous transplantation for lymphoma. Weisdorf, D. J. & Arora ...
The potential of RPE transplantation was demonstrated in animal models. Rejection of allogeneic homologous transplants in ... Transplantation of the RPE in AMD PROGRESS IN RETINAL AND EYE RESEARCH Binder, S., Stanzel, B. V., Krebs, I., Glittenberg, C. ... Perspective: Tissue engineering for RPE transplantation in AMD SPEKTRUM DER AUGENHEILKUNDE Stanzel, B. V., Englander, M., ... This article reviews mechanisms leading to RPE dysfunction in aging and AMD, laboratory studies on RPE transplantation, and ...
Homologous Transplantation Medicine & Life Sciences 100% * Bone Marrow Transplantation Medicine & Life Sciences 90% ... In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 5, 05.2019, p. 868-882.. Research output: Contribution to journal ... keywords = "Bone marrow transplantation, Euclidean distance, Graft-versus-host disease, T cell receptor recombination, T cell ... This TCR-β VJ segment translational symmetry is preserved post-transplantation and even in cases of acute graft-versus-host ...
Hematopoietic stem cell transplantation for patients with Wiskott-Aldrich syndrome]. Rev Med Chil. 2007 Jul. 135(7):917-23. [ ... and several Wiskott-Aldrich syndrome proteins verprolin homologous (WAVE). [18, 19, 20, 21] ... Hematopoietic stem cell transplantation is the most reliable curative approach for patients with HLA-matched family or ... Unrelated bone marrow transplantation with a reduced toxicity myeloablative conditioning regimen in Wiskott-Aldrich syndrome. J ...
... of oneself would be created in order to be frozen away in case of need for homologous tissues or organs for transplantation; ...
Homologous Transplantation Medicine & Life Sciences 95% * Bone Marrow Transplantation Medicine & Life Sciences 87% ... In: Bone Marrow Transplantation, Vol. 22, No. 10, 1998, p. 981-987.. Research output: Contribution to journal › Article › peer- ... Lymphoproliferative disorders following allogeneic bone marrow transplantation: The Vancouver experience. I. N.M. Micallef, M. ... Lymphoproliferative disorders following allogeneic bone marrow transplantation : The Vancouver experience. / Micallef, I. N.M. ...
Transplantation, Homologous. en_US. dc.subject.mesh. Treatment Outcome. en_US. dc.subject.mesh. Virus Replication - Drug ... The treatment criteria were met by de novo patients at 8.4 ± 6.2 months (range, 1-18 months) after transplantation. Suppression ... The treatment criteria were met by de novo patients at 8.4 ± 6.2 months (range, 1-18 months) after transplantation. Suppression ... Eleven de novo patients (91.7%) who underwent transplantation between 1996 and 2000 and 15 existing patients (39.5%) who ...
Homologous Transplantation 12% * Sepsis 11% * Survival 11% * Sciatic Nerve 11% * Bone Marrow Transplantation 11% ...
use TRANSPLANTATION, HOMOLOGOUS to search TRANSPLANTATION, ALLOGENEIC 1975-79. History Note:. 65; TRANSPLANTATION, ALLOGENEIC ... Allogeneic Transplantation Allografting Grafting, Allogeneic Homografting Homologous Transplantation Transplantation, ... Allogeneic Transplantation. Allografting. Grafting, Allogeneic. Homografting. Homologous Transplantation. Transplantation, ... Transplantation, Homologous - Preferred Concept UI. M0021836. Scope note. Transplantation between individuals of the same ...
Keywords : Dental implants.; Transplantation.; Transplantation homologous.. · abstract in Portuguese · text in English · pdf in ...
Allogeneic Cells/transplantation Transplantation, Homologous Enzymes/therapeutic use Enzyme Therapy Epidermis/cytology ...
Transplantation, Autologous. en_US. dc.subject.mesh. Transplantation, Homologous. en_US. dc.title. Newly diagnosed multiple ...
Allogeneic Cells/transplantation Transplantation, Homologous Enzymes/therapeutic use Enzyme Therapy Epidermis/cytology ...
Transplantation, Homologous, Myelodysplastic Syndromes, Drug Therapy, Transplantation Conditioning, Health Services for the ... Bone Marrow Transplantation, Surgical Procedures, Operative, Nursing Care, Histocompatibility, Immunogenetics, Transplantation ... Peripheral Blood Stem Cell Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Stem Cell Transplantation, ... Bone Marrow Transplantation, Nursing, Pediatrics, Public Health, 50230, Primary Health Care, Delivery of Health Care, Health ...
Transplantation, Homologous, Myelodysplastic Syndromes, Drug Therapy, Transplantation Conditioning, Health Services for the ... Bone Marrow Transplantation, Surgical Procedures, Operative, Nursing Care, Histocompatibility, Immunogenetics, Transplantation ... Peripheral Blood Stem Cell Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Stem Cell Transplantation, ... Bone Marrow Transplantation, Nursing, Pediatrics, Public Health, 50230, Primary Health Care, Delivery of Health Care, Health ...
Reply: Staying safe during gluteal fat transplantation. Villanueva, N. L., Del Vecchio, D. A., Afrooz, P. N. & Rohrich, R. J., ... Staying Safe during Gluteal Fat Transplantation. Villanueva, N. L., Del Vecchio, D. A., Afrooz, P. N., Carboy, J. A. & Rohrich ...
Homologous Transplantation 53% * Infections 45% * Transplantation 36% * Minor Histocompatibility Antigens 35% * Listeria ...
Rashidi, A., Ebadi, M. & Cashen, A. F., Apr 1 2016, In: Bone Marrow Transplantation. 51, 4, p. 521-528 8 p.. Research output: ... Cashen, A. F., Lazarus, H. M. & Devine, S. M., May 2007, In: Bone Marrow Transplantation. 39, 10, p. 577-588 12 p.. Research ... Cytokines and stem cell mobilization for autologous and allogeneic transplantation.. Cashen, A. F., Link, D., Devine, S. & ... Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. Ali, A. M., Dehdashti ...
Stem Cell Transplantation, Sus scrofa, Tissue Engineering, Tissue Scaffolds/chemistry, Transplantation, Homologous, Wound ...
  • Provincial registries were available and used for identifying lung malignancies and solid organ transplantation. (
  • Transplant international : official journal of the European Society for Organ Transplantation 2022 5 35 10099. (
  • To address the progression of immune-related constraints on organ transplantation, the first part of this thesis contains a historical analysis tracing early transplant motivations and the events that led to the discoveries broadly related to tolerance, rejection, and compatibility. (
  • Despite the advancement of those concepts over time, this early history shows that immunosuppression was one of the earliest limiting barriers to successful organ transplantation, and remains one of the most significant technical challenges. (
  • Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. (
  • Patients at risk for acute graft versus host disease (GVHD) and chronic GVHD are those undergoing allogeneic hematopoietic-cell transplantation (HCT). (
  • However, in patients with primary refractory or relapsed disease, high-dose therapy (HDT) and autologous or peripheral-blood stem-cell transplantation (ASCT or PBSCT) represents the best curative option. (
  • Functional activity of peripheral blood granulocytes was assessed in seven patients and in their normal donors following allogeneic bone marrow transplantation (BMT). (
  • It has been proposed that bone marrow or hematopoietic stem-cell transplantation, and resulting (mixed) hematopoietic chimerism, lead to immunological tolerance to organs of the same donor. (
  • We discuss here recent advances obtained by combining regulatory T cell infusion with bone-marrow transplantation. (
  • The associations identified thus far are of a broadly statistical nature, precluding precise modeling of outcomes based on T cell repertoire development following bone marrow transplantation (BMT). (
  • Bone Marrow Transplantation , 22 (10), 981-987. (
  • To determine whether age over 40 years is associated with adverse outcome after allogeneic bone marrow transplantation for leukemia. (
  • These data indicate that among leukemia patients over 30 years of age at the time of allogeneic bone marrow transplantation, increasing age into the fifth decade does not adversely affect outcome after transplants from HLA-identical siblings. (
  • Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. (
  • Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogeneic bone marrow transplantation (BMT). (
  • Dr. Jay Sarthy is a hematologist-oncologist who specializes in pediatric bone marrow transplantation for children with blood cancers and rare genetic conditions, such as telomere syndromes. (
  • Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype. (
  • Acute graft versus host disease (GVHD) involving desquamating skin lesions in a patient after allogeneic bone marrow transplantation for myelodysplasia. (
  • At present, the only definitive cure is bone marrow transplantation. (
  • [ 39 ] The IL-10-592A allelic polymorphism is a marker for a favorable outcome after transplantation in recipients of hematopoietic stem cells from HLA-identical siblings. (
  • Of patients undergoing renal transplantation during a recent 18-month period 42 per cent had significant urologic abnormalities. (
  • Patient survival after intestinal transplantation has improved in the past 3-5 years and now approaches that of other solid organ allograft recipients, including liver and kidney, and is similar to survival on permanent therapy with parenteral nutrition. (
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2022 3 28 (8): 1306-1320. (
  • FA is the result of a genetic defect in a cluster of proteins responsible for DNA repair via homologous recombination . (
  • 개별 변이체는 상동 유전자 재조합 (homologous recombination)에 의해 정상 세포에 존재하는 한 쌍의 개별 유전자들 중 하나가 결손된 상태입니다 (그림 참조). (
  • Homologous transplantation or autotransplantation is a surgical procedure that transplants teeth or dental embryos from one alveolar to the other in the same person. (
  • This TCR-β VJ segment translational symmetry is preserved post-transplantation and even in cases of acute graft-versus-host disease (aGVHD), suggesting that GVHD occurrence represents a polyclonal donor T cell response to recipient antigens. (
  • Allogeneic hematopoietic stem cell transplantation is curative but it requires a histocompatible donor and is associated with significant morbidity and mortality, so it is reserved for severe cases of PNH with aplastic anemia or transformation to leukemia. (
  • The immunosuppressive regimens currently used in transplantation to prevent allograft destruction by the host's immune system have deleterious side effects and fail to control chronic rejection processes. (
  • Nearly all patients discharged after intestinal transplantation have good allograft function and have been weaned from total parenteral nutrition. (
  • First Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation, Ottawa, 29 November to 1December 2004 : report. (
  • A survey was carried out among EBMT (European Group for Blood and Marrow Transplantation) centres of the practical details of the prophylaxis and treatment of acute GVHD. (
  • A hyperacute form of GVHD has been described as a disorder including fever, generalized erythroderma, and desquamation developing 7-14 days after transplantation. (
  • Complications are more common and often more severe during the initial hospitalization period after intestinal transplantation than they are after transplantation of other solid organs. (
  • Report of the Human Fetal Tissue Transplantation Research Panel, December 1988 / consultants to the Advisory Committee to the Director, National Institutes of Health. (
  • Over the past 15 years, intestinal transplantation for the treatment of intestinal failure has changed from a desperate last-ditch effort into a standard therapy for which a good outcome is expected. (
  • Eleven de novo patients (91.7%) who underwent transplantation between 1996 and 2000 and 15 existing patients (39.5%) who underwent transplantation between 1983 and 1995 received preemptive lamivudine therapy for 32.6 ± 13.3 months. (
  • Not only has the average homologous blood requirement decreased, but the percentage of patients requiring no homologous blood products has sharply increased, from 4% to 68% in one study involving vascular surgery patients. (
  • Intraoperative cell salvage has been used in a variety of surgical settings, and its ability to reduce homologous blood use is well documented. (
  • Outcomes of patients who underwent transplantation before or after institution of this preemptive management strategy (in January 1996) were compared. (
  • Patients with a variety of abnormalities of the urinary tract had a transplantation success rate comparable to that of azotemic patients with normal urinary systems. (
  • Our purpose was to study retinal pigment epithelium (RPE) wound healing in patients with age-related macular degeneration (AMD).Abrasive debridement of nasal RPE was performed with a metal cannula during pars plana vitrectomy for foveal choroidal neovascularization (CNV) membrane excision combined with simultaneous autologous RPE transplantation. (
  • The treatment criteria were met by de novo patients at 8.4 ± 6.2 months (range, 1-18 months) after transplantation. (
  • In this review we analyzed the results of the most important salvage chemotherapy combinations as well as allogeneic transplantations to clarify the optimal treatment options for patients with resistant/relapsing HD. (
  • Averaged creatinine clearance over the period 0 to 24 hours after transplantation was 20.1 +/- 14.7 ml/min in patients receiving active treatment and 18.2 +/- 13.7 ml/min in those receiving placebo. (
  • Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. (
  • Biology of Blood and Marrow Transplantation , 25 (5), 868-882. (
  • Many, though not all, Jehovah's Witnesses will accept cell salvage, and it may be used in cases where obtaining homologous blood is difficult because of rare blood types or multiple antibodies. (
  • Treatment of intestinal failure: intestinal transplantation. (
  • The cost of the initial hospitalization period is one to two times the cost of permanent total parenteral nutrition for 1 year, which means that, in most cases, intestinal transplantation is cost-saving within 2 years of transplantation. (